Evidence map›Paper›PMID 28115190›Full record

ArticleThe Journal of urology2017

Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study.

Padraic G O'Malley, Daniel P Nguyen, Bashir Al Hussein Al Awamlh, Guojiao Wu, Ian M Thompson, Martin Sanda, Mark Rubin, John T Wei, Richard Lee, Paul Christos and 2 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. African-American Prostate Cancer Disparities.Current urology reports · 2017
    Review
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 2 countries.

Padraic G O'MalleyDepartment of Urology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York. Electronic address: pao9029@med.cornell.edu.
Daniel P NguyenDepartment of Urology, Universität Bern, Bern, Switzerland.
Bashir Al Hussein Al AwamlhDepartment of Urology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York.
Guojiao WuDepartment of Healthcare Policy and Research, Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York.
Ian M ThompsonDepartment of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
Martin SandaDepartment of Urology, Emory University School of Medicine, Atlanta, Georgia.
Mark RubinDepartment of Pathology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York.
John T WeiDepartment of Urology, University of Michigan, Livonia, Michigan.
Richard LeeDepartment of Urology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York.
Paul ChristosDepartment of Healthcare Policy and Research, Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York.
Christopher BarbieriDepartment of Urology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York.
Douglas S ScherrDepartment of Urology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York.
New York Hospital Queens · USCornell University · USNewYork–Presbyterian Hospital · USEmory University · USPresbyterian Hospital · USThe University of Texas Health Science Center at San Antonio · USUniversity of Bern · CHUniversity of Michigan–Ann Arbor · US

Funding

Clinical and Translational Science CenterUL1TR000457 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$46.0M
Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas SouthwesternU01CA113913 · NCI · EMORY UNIVERSITY · PI Martin G. Sanda · 2005 to 2026
$16.4M
NCATS NIH HHS UL1 TR000457NCI NIH HHS U01 CA113913
6 · The paper itself

Abstract

purposeTo our knowledge it is unknown whether urinary biomarkers for prostate cancer have added utility to clinical risk calculators in different racial groups. We examined the utility of urinary biomarkers added to clinical risk calculators for predicting prostate cancer in African American and nonAfrican American men. MATERIALS AND

methodsDemographics, PCPT (Prostate Cancer Prevention Trial) risk scores, data on the biomarkers data PCA3 (prostate cancer antigen 3) and T2ERG (transmembrane protease serine 2 and v-ets erythroblastosis virus E26 oncogene homolog gene fusion), and biopsy pathology features were prospectively collected on 718 men as part of EDRN (Early Detection Research Network). Utility was determined by generating ROC curves and comparing AUC values for the baseline multivariable PCPT model and for models containing biomarker scores.

resultsPCA3 and T2ERG added utility for the prediction of prostate cancer and clinically significant prostate cancer when combined with the PCPT Risk Calculator. This utility was seen in nonAfrican American men only for PCA3 (AUC 0.64 increased to 0.75 for prostate cancer and to 0.69-0.77 for clinically significant prostate cancer, both p <0.001) and for T2ERG (AUC 0.64-0.74 for prostate cancer, p <0.001, and 0.69-0.73 for clinically significant prostate cancer, p = 0.029). African American men did not have an added benefit with the addition of biomarkers, including PCA3 (AUC 0.75-0.77, p = 0.64, and 0.65-0.66, p = 0.74) and T2ERG (AUC 0.75-0.74, p = 0.74, and 0.65-0.64, p = 0.88), for prostate cancer and clinically significant prostate cancer, respectively. Limitations include the small number of African American men (72). The post hoc subgroup analysis nature of the study limited findings to being hypothesis generating.

conclusionsAs novel biomarkers are discovered, clinical utility should be established across demographically diverse cohorts.

Indexed as

Black or African AmericanAntigens, NeoplasmBiomarkers, TumorHumansMaleOncogene Proteins, FusionProspective StudiesProstatic NeoplasmsProto-Oncogene Protein c-ets-2Risk AssessmentSerine EndopeptidasesAntigens, NeoplasmBiomarkers, TumorETS2 protein, humanOncogene Proteins, Fusionprostate cancer antigen 3, humanProto-Oncogene Protein c-ets-2Serine EndopeptidasesTMPRSS2 protein, humanAfrican Americansbiomarkersgene fusionhumanprostate cancer antigen 3prostatic neoplasmstumor

Identifiers

PMID28115190
PMCPMC5568076
OpenAlexW2573802705

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.